Evaluating the long-term effects of a booster dose of MVA-BN vaccine for monkeypox
Evaluation of Long-term Immunogenicity of a Boost Dose of MVA-BN Vaccine
This study is testing how well a booster dose of the MVA-BN vaccine works over time in men over 18 who have already had two doses to help protect against monkeypox.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 90 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Assistance Publique - Hôpitaux de Paris Academic / other |
| Locations | 1 site (Paris, Paris) |
| Trial ID | NCT06885853 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the long-term immunogenicity of a booster dose of the MVA-BN vaccine, which is used to prevent monkeypox. The study focuses on men over 18 years who have previously received two doses of the vaccine and are eligible for a booster. Given the recent emergence of monkeypox outbreaks, particularly among high-risk populations, this research is critical for understanding the vaccine's effectiveness over time. Participants will also be eligible for HIV pre-exposure prophylaxis (PrEP) treatment, which adds an important layer to the study's public health implications.
Who should consider this trial
Good fit: Ideal candidates for this study are men over 18 who have received two doses of the MVA-BN vaccine and are eligible for a booster.
Not a fit: Patients with a history of confirmed monkeypox or contraindications to vaccination will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance vaccination strategies and improve protection against monkeypox for at-risk populations.
How similar studies have performed: Other studies have shown promising results with similar vaccine approaches, particularly in enhancing immunogenicity through booster doses.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Men aged over 18 years * Have received two doses of MVA-BN vaccine as an initial schedule * Eligible for a booster dose of MVA-BN (according to the HAS recommendation) * Be eligible and wish to initiate PrEP-HIV treatment or be followed for PrEP-HIV treatment * Covered by social security (excluding AME) Exclusion Criteria: * History of mpox (virologically confirmed) * Be under guardianship or curatorship * Be subject to a judicial protection measure * Have a contraindication to vaccination against mpox
Where this trial is running
Paris, Paris
- CIC 1417Cochin-Pasteur — Paris, Paris, France (Recruiting)
Study contacts
- Principal investigator: Liem Binh Luong Nguyen, Degree medical doctor — Assistance Publique - Hôpitaux de Paris
- Study coordinator: Liem Binh Luong Nguyen, Degree medical doctor
- Email: liem.luong@aphp.fr
- Phone: 0033 1 58 41 28 58
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.